|
|
利妥昔单抗治疗系统性红斑狼疮合并慢性活动性EB病毒感染1例并文献复习
|
Abstract:
目的：探讨系统性红斑狼疮合并慢性活动性EB病毒感染的临床特征及诊治方法。方法：报道1例利妥昔单抗治疗系统性红斑狼疮合并慢性活动性EB病毒感染患者的临床资料，分析其临床特点及诊疗经过，复习国内外相关文献。结果：29岁女性患者，面部红斑9年余，1年内因发热多次住院，本次因反复发热半月伴咳嗽咽痛、头晕恶心、腹泻腹胀入院，结合病史查体及辅助检查，诊断为系统性红斑狼疮合并慢性活动性EB病毒感染，经利妥昔单抗500 mg q2w治疗后病情好转。结论：系统性红斑狼疮合并慢性活动性EB病毒感染病情复杂，应尽早明确诊断，本例应用利妥昔单抗有效，为临床治疗方案提供思路。
Objective: To investigate the clinical features, diagnosis and treatment of systemic lupus erythematosus complicated with chronic active Epstein-Barr virus infection. Methods: The clinical data of a patient with systemic lupus erythematosus complicated with chronic active Epstein-Barr virus infection were reported, the clinical characteristics, diagnosis and treatment process were analyzed, and the relevant literature at home and abroad was reviewed. Results: A 29-year-old female patient with facial erythema for more than 9 years was hospitalized for fever for several times within 1 year, and was admitted to the hospital for recurrent fever for half a month with cough and sore throat, dizziness, nausea, diarrhea and abdominal distension, combined with medical history and physical examination and auxiliary examinations, she was diagnosed with systemic lupus erythematosus with chronic active Epstein-Barr virus infection, and her condition improved after treatment with rituximab 500 mg q2w. Conclusion: The condition of systemic lupus erythematosus complicated with chronic active Epstein-Barr virus infection is complex, and the diagnosis should be made as soon as possible. The application of rituximab in this case is effective and provides ideas for clinical treatment options.
| [1] | 中华医学会风湿病学分会, 国家皮肤与免疫疾病临床医学研究中心, 中国系统性红斑狼疮研究协作组. 2020中国系统性红斑狼疮诊疗指南[J]. 中华内科杂志, 2020, 59(3): 172-185. https://doi.org/10.3760/cma.j.issn.0578-1426.2020.03.002 |
| [2] | Arai, A. (2021) Chronic Active Epstein-Barr Virus Infection: The Elucidation of the Pathophysiology and the Development of Therapeutic Methods. Microorganisms, 9, Article No. 180. https://doi.org/10.3390/microorganisms9010180 |
| [3] | Fujiwara, S. and Nakamura, H. (2020) Chronic Active Epstein-Barr Virus Infection: Is It Immunodeficiency, Malignancy, or Both? Cancers, 12, Article No. 3202. https://doi.org/10.3390/cancers12113202 |
| [4] | Jog, N.R., Young, K.A., Munroe, M.E., Harmon, M.T., Guthridge, J.M., Kelly, J.A., et al. (2019) Association of Epstein-Barr Virus Serological Reactivation with Transitioning to Systemic Lupus Erythematosus in At-Risk Individuals. Annals of the Rheumatic Diseases, 78, 1235-1241. https://doi.org/10.1136/annrheumdis-2019-215361 |
| [5] | 中国老年保健协会淋巴瘤专业委员会, 中华医学会血液学分会. 利妥昔单抗静脉快速输注中国专家共识(2020年版) [J]. 白血病？淋巴瘤, 2021, 30(1): 1-4. https://doi.org/10.3760/cma.j.cn115356-20201030-00259 |
| [6] | Karrar, S. and Cunninghame Graham, D.S. (2018) Review: Abnormal B Cell Development in Systemic Lupus Erythematosus: What the Genetics Tell Us. Arthritis & Rheumatology, 70, 496-507. https://doi.org/10.1002/art.40396 |
| [7] | Rees, F., Doherty, M., Grainge, M., Lanyon, P., Davenport, G. and Zhang, W. (2016) Burden of Comorbidity in Systemic Lupus Erythematosus in the UK, 1999-2012. Arthritis Care & Research, 68, 819-827. https://doi.org/10.1002/acr.22751 |
| [8] | Tian, J., Zhang, D., Yao, X., Huang, Y. and Lu, Q. (2022) Global Epidemiology of Systemic Lupus Erythematosus: A Comprehensive Systematic Analysis and Modelling Study. Annals of the Rheumatic Diseases, 82, 351-356. https://doi.org/10.1136/ard-2022-223035 |
| [9] | 沈南, 赵毅, 段利华, 等. 系统性红斑狼疮诊疗规范[J]. 中华内科杂志, 2023, 62(7): 775-784. https://doi.org/10.3760/cma.j.cn112138-20221027-00793 |
| [10] | Draborg, A., J？rgensen, J., Müller, H., Nielsen, C., Jacobsen, S., Iversen, L., et al. (2012) Epstein-Barr Virus Early Antigen Diffuse (EBV-EA/D)-Directed Immunoglobulin a Antibodies in Systemic Lupus Erythematosus Patients. Scandinavian Journal of Rheumatology, 41, 280-289. https://doi.org/10.3109/03009742.2012.665944 |
| [11] | Wood, R.A., Guthridge, L., Thurmond, E., Guthridge, C.J., Kheir, J.M., Bourn, R.L., et al. (2021) Serologic Markers of Epstein-Barr Virus Reactivation Are Associated with Increased Disease Activity, Inflammation, and Interferon Pathway Activation in Patients with Systemic Lupus Erythematosus. Journal of Translational Autoimmunity, 4, Article ID: 100117. https://doi.org/10.1016/j.jtauto.2021.100117 |
| [12] | Hanlon, P., Avenell, A., Aucott, L. and Vickers, M.A. (2014) Systematic Review and Meta-Analysis of the Sero-Epidemiological Association between Epstein-Barr Virus and Systemic Lupus Erythematosus. Arthritis Research & Therapy, 16, R3. https://doi.org/10.1186/ar4429 |
| [13] | Laurynenka, V., Ding, L., Kaufman, K.M., James, J.A. and Harley, J.B. (2022) A High Prevalence of Anti-EBNA1 Heteroantibodies in Systemic Lupus Erythematosus (SLE) Supports Anti-EBNA1 as an Origin for SLE Autoantibodies. Frontiers in Immunology, 13, Article ID: 830993. https://doi.org/10.3389/fimmu.2022.830993 |
| [14] | Li, Z., Zeng, S., Wu, H. and Zhou, Y. (2018) The Risk of Systemic Lupus Erythematosus Associated with Epstein-Barr Virus Infection: A Systematic Review and Meta-Analysis. Clinical and Experimental Medicine, 19, 23-36. https://doi.org/10.1007/s10238-018-0535-0 |
| [15] | Piroozmand, A., Haddad Kashani, H. and Zamani, B. (2017) Correlation between Epstein-Barr Virus Infection and Disease Activity of Systemic Lupus Erythematosus: A Cross-Sectional Study. Asian Pacific Journal of Cancer Prevention, 18, 523-527. https://doi.org/10.22034/APJCP.2017.18.2.523 |
| [16] | Han, L., Zhang, Y., Wang, Q., Xin, M., Yang, K., Lei, K., et al. (2018) Epstein-Barr Virus Infection and Type I Interferon Signature in Patients with Systemic Lupus Erythematosus. Lupus, 27, 947-954. https://doi.org/10.1177/0961203317753069 |
| [17] | Wang, S., Wang, S. and Singh, S. (2020) Development of Systemic Lupus Erythematosus after Infectious Mononucleosis in a 64-Year-Old Woman. Journal of Investigative Medicine High Impact Case Reports, 8, 2324709620961613. https://doi.org/10.1177/2324709620961613 |
| [18] | Iardino, A., Amar, Z. and Ahmed, Y. (2018) Epstein-Barr-Positive Classical Hodgkin Lymphoma-Associated Haemophagocytic Lymphohistocytiosis: A Rare Case. BMJ Case Reports, 2018, bcr-2018-225262. https://doi.org/10.1136/bcr-2018-225262 |
| [19] | 许书添, 董建华, 李世军. 系统性红斑狼疮合并噬血细胞综合征[J]. 肾脏病与透析肾移植杂志, 2019, 28(3): 293-297. https://doi.org/10.3969/j.issn.1006-298X.2019.03.021 |
| [20] | Ichikawa, S., Fukuhara, N., Shirai, T., Ishii, T., Ichinohasama, R. and Harigae, H. (2020) Extranasal Extranodal NK/T-Cell Lymphoma Associated with Systemic Lupus Erythematosus. International Journal of Hematology, 112, 592-596. https://doi.org/10.1007/s12185-020-02914-w |
| [21] | Yamashita, H., Shimizu, A., Tsuchiya, H., Takahashi, Y., Kaneko, H., Kano, T., et al. (2014) Chronic Active Epstein-Barr Virus Infection Mimicking Autoimmune Hepatitis Exacerbation in a Patient with Systemic Lupus Erythematosus. Lupus, 23, 833-836. https://doi.org/10.1177/0961203314527367 |
| [22] | Cohen, J.I., Jaffe, E.S., Dale, J.K., Pittaluga, S., Heslop, H.E., Rooney, C.M., et al. (2011) Characterization and Treatment of Chronic Active Epstein-Barr Virus Disease: A 28-Year Experience in the United States. Blood, 117, 5835-5849. https://doi.org/10.1182/blood-2010-11-316745 |
| [23] | Dunmire, S.K., Verghese, P.S. and Balfour, H.H. (2018) Primary Epstein-Barr Virus Infection. Journal of Clinical Virology, 102, 84-92. https://doi.org/10.1016/j.jcv.2018.03.001 |
| [24] | Arai, A. (2019) Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features under the 2016 WHO Classification and Mechanisms of Development. Frontiers in Pediatrics, 7, Article No. 14. https://doi.org/10.3389/fped.2019.00014 |
| [25] | 郑钰, 周菊. 慢性活动性EB病毒感染的研究进展[J]. 国际输血及血液学杂志, 2023, 46(4): 358-364. https://doi.org/10.3760/cma.j.cn511693-20220613-00094 |
| [26] | 耿研, 武丽君, 谢其冰, 等. 生物制剂在系统性红斑狼疮中应用的中国专家共识(2024版) [J]. 中华风湿病学杂志, 2024, 28(2): 78-92. https://doi.org/10.3760/cma.j.cn141217-20230711-00190-1 |
| [27] | Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S., et al. (2023) EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update. Annals of the Rheumatic Diseases, 83, 15-29. https://doi.org/10.1136/ard-2023-224762 |
| [28] | Mok, C.C., Hamijoyo, L., Kasitanon, N., Chen, D.Y., Chen, S., Yamaoka, K., et al. (2021) The Asia-Pacific League of Associations for Rheumatology Consensus Statements on the Management of Systemic Lupus Erythematosus. The Lancet Rheumatology, 3, e517-e531. https://doi.org/10.1016/s2665-9913(21)00009-6 |
| [29] | Marinho, A., Delgado Alves, J., Fortuna, J., Faria, R., Almeida, I., Alves, G., et al. (2023) Biological Therapy in Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Sj？gren’s Syndrome: Evidence-and Practice-Based Guidance. Frontiers in Immunology, 14, Article ID: 1117699. https://doi.org/10.3389/fimmu.2023.1117699 |
